Comparative Pharmacology
Head-to-head clinical analysis: VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER versus VANCOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER versus VANCOR.
VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER vs VANCOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of the peptidoglycan precursor, blocking transglycosylation and transpeptidation.
Inhibits cell wall synthesis by binding to the D-alanyl-D-alanine terminus of peptidoglycan precursors, blocking transglycosylation and transpeptidation.
15–20 mg/kg IV every 8–12 hours (max 2 g per dose), adjusted based on trough concentrations (target 10–20 mg/L).
Vancomycin 15-20 mg/kg IV every 8-12 hours, with target trough 10-20 mcg/mL; for serious infections, consider loading dose 25-30 mg/kg IV.
None Documented
None Documented
Terminal half-life: 4-6 hours in adults with normal renal function. Extends significantly in renal impairment (up to 7-10 days in anuria). Requires therapeutic drug monitoring.
Terminal elimination half-life is 4-6 hours in adults with normal renal function; can extend to 7-9 days in anuric patients, necessitating therapeutic drug monitoring.
Renal elimination of unchanged drug by glomerular filtration: approximately 80-90% within 24 hours. Biliary/fecal excretion: less than 5%.
Renal excretion of unchanged drug accounts for 80-90% of clearance via glomerular filtration; minor biliary excretion (<5%) and fecal elimination (<5%).
Category A/B
Category C
Glycopeptide Antibiotic
Glycopeptide Antibiotic